All In Biotech

Drug Trial Radar · NCT07924618

Ocular Changes in Patients Using Tirzepatide or Semaglutide

Evaluation of Optic Nerve Head, Retinal Changes, and Choroidal Blood Flow in Patients With Diabetes and Obesity Using Tirzepatide or Semaglutide

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Mar 1, 2026

Primary completion

Sep 17, 2027

Study completion Sep 17, 2027

Sponsor

Lead sponsor
Istanbul UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 9, 2026

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This prospective observational study aims to evaluate ocular structural and microvascular changes in adults with obesity who are receiving semaglutide or tirzepatide as part of routine clinical care. Participants with and without type 2 diabetes mellitus will be included. Participants will undergo ophthalmologic examinations at baseline and during follow-up. Changes in optic nerve head parameters, retinal thickness, retinal and choroidal microvascular parameters, and choroidal thickness will be assessed using optical coherence tomography (OCT), optical coherence tomography angiography (OCT-A), and other routine ophthalmologic examination methods. The study will compare ocular measurements obtained at baseline and during follow-up to investigate changes associated with semaglutide or tirzepatide treatment over a period of up to 18 months.

Conditions

  • Type 2 Diabetes Mellitus
  • Obesity

Interventions

  • SemaglutideDrug

    Semaglutide is prescribed as part of routine clinical care. Treatment is not assigned by the study protocol. Ocular structural and vascular parameters are evaluated before treatment and during follow-up.

  • TirzepatideDrug

    Tirzepatide is prescribed as part of routine clinical care. Treatment is not assigned by the study protocol. Ocular structural and vascular parameters are evaluated before treatment and during follow-up.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Retinal Nerve Fiber Layer ThicknessTime frame: Baseline to up to 18 months
  2. Change in Retinal ThicknessTime frame: Baseline to up to 18 months
  3. Change in Superficial Retinal Vessel DensityTime frame: Baseline to 18 months
  4. Change in Deep Retinal Vessel DensityTime frame: Baseline to 18 months
  5. Change in Foveal Avascular Zone AreaTime frame: Baseline to 18 months
  6. Change in Choriocapillaris Flow Deficit PercentageTime frame: Baseline to 18 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Istanbul University, Istanbul Faculty of Medicine

    Istanbul, Istanbul, Turkey (Türkiye) · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.